Efficacy and safety of BNT162b2 mRNA vaccine in a cohort of 90 transfusion dependent thalassemia patients
M. Marziali
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorP. Pugliese
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorA. A. Losardo
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorM. Ribersani
Hematology, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorE. Anastasi
Department of Experimental Medicine, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorA. Angeloni
Department of Experimental Medicine, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorA. Pavan
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorCorresponding Author
G. Gentile
Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy
Correspondence
G. Gentile, Department of Translational and Precision Medicine Sapienza Università di Roma, Rome, Italy.
Email: [email protected]
Search for more papers by this authorM. Marziali
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorP. Pugliese
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorA. A. Losardo
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorM. Ribersani
Hematology, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorE. Anastasi
Department of Experimental Medicine, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorA. Angeloni
Department of Experimental Medicine, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorA. Pavan
Immunohematology and Transfusion Medicine Unit, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
Search for more papers by this authorCorresponding Author
G. Gentile
Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy
Correspondence
G. Gentile, Department of Translational and Precision Medicine Sapienza Università di Roma, Rome, Italy.
Email: [email protected]
Search for more papers by this authorOpen Research
DATA AVAILABILITY STATEMENT
The data presented in this study are available on request from the corresponding author, due to restrictions for privacy and ethical.
REFERENCES
- 1Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β-thalassemia. Eur J Haematol. 2020; 105(6): 692-703.
- 2El-Battrawy I, Longo F, Núñez Gil IJ, et al. Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: data from an international registry. J Cell Mol Med. 2022; 9: 2520-2528.
10.1111/jcmm.17026 Google Scholar
- 3Longo F, Gianesin B, Voi V, et al. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection. Am J Hematol. 2022; 97(2): E75-E78.
- 4Ghoti H, Zreid H, Ghoti I, et al. Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study. EClinicalMedicine. 2023; 62:102096.
- 5Anastasi E, Marziali M, Preziosi A, et al. A humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in thalassemia major patients. Microbes Infect. 2022; 24(6–7):104976.
- 6Delaporta P, Terpos E, Solomou EE, et al. Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia. Br J Haematol. 2022; 197(5): 576-579.
- 7Carsetti R, Agrati C, Pinto VM, et al. Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose. Blood. 2022; 140(15): 1735-1738.
- 8 WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020 https://www.who.int/publications-detail/clinical-management-of-severeacute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-issuspected
- 9Falasca F, Sciandra I, Di Carlo D, et al. Detection of SARS-COV N2 gene: very low amounts of viral RNA or false positive? J Clin Virol Dec. 2020; 133:104660.
- 10Marziali M, Ribersani M, Losardo AA, et al. COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major. Clin Case Rep. 2020; 8(12): 3139-3142.
Citing Literature
